PharmaShots Weekly Snapshots (April 25-29, 2022)
AstraZeneca Reports First Patient Dosing in P-III PACIFIC-9 Study for NSCLC
Published: Apr 29, 2022 | Tags: AstraZeneca, P-III, PACIFIC-9 Study, NSCLC
Pfizer to Initiate P-III Study of Fordadistrogene Movaparvovec After FDA Lift Clinical Hold
Published: Apr 29, 2022 | Tags: Pfizer, Fordadistrogene Movaparvovec, FDA, Clinical Hold, CIFFREO
Abbott Launches Amplatzer Steerable Delivery Sheath for Amulet Device to Treat Atrial Fibrillation
Published: Apr 29, 2022 | Tags: Abbott, Launches, Amplatzer Steerable Delivery Sheath, Amulet Device, Atrial Fibrillation
Genentech Reports Three-Year Data of Evrysdi (risdiplam) in (FIREFISH) Study for the Treatment of Type 1 Spinal Muscular Atrophy
Published: Apr 29, 2022 | Tags: Genentech, Evrysdi, risdiplam, FIREFISH Study, Type 1, Spinal Muscular Atrophy
BMS’ Camzyos (mavacamten) Receives the US FDA’s Approval for the Treatment of Symptomatic New York Heart Association Class II-III Obstructive HCM
Published: Apr 29, 2022 | Tags: BMS, Camzyos, mavacamten, US, FDA, Approval, Symptomatic, New York, Heart Association, Class II-III, Obstructive HCM
Published: Apr 29, 2022 | Tags: Abbvie, Plexium, Targeted Protein Degradation, Therapies, Neurological Conditions
Published: Apr 28, 2022 | Tags: AstraZeneca, Ultomiris, ravulizumab-cwvz, US, FDA, Approval, Generalized Myasthenia Gravis
Published: Apr 28, 2022 | Tags: Transcenta, P-I Study, TST002, Osteoporosis, China
Published: Apr 28, 2022 | Tags: Amgen, Repatha, evolocumab, P-III, FOURIER, OLE Studies, Atherosclerotic Cardiovascular Disease
Published: Apr 28, 2022 | Tags: Harmony Biosciences, P-III, INTUNE, Withdrawal Study, Pitolisant, Idiopathic Hypersomnia
Published: Apr 28, 2022 | Tags: Vifor, Cara, Kapruvia, difelikefalin, EC, Approval, Pruritus, Hemodialysis
Published: Apr 28, 2022 | Tags: Statera, Immune, Naltrexone, Met-Enkephalin, Immune-Related Diseases
Published: Apr 27, 2022 | Tags: Pfizer, Biohaven, Vydura, rimegepant, EC, Marketing Authorization, Migraine, Prophylaxis, Episodic Migraine
Published: Apr 27, 2022 | Tags: BeiGene, Tislelizumab, P-III, RATIONALE 306 Trial, Esophageal Squamous Cell Carcinoma
Published: Apr 27, 2022 | Tags: Novaliq, Cyclasol, P-III, ESSENCE-2 Trial, Dry Eye Disease, ASCRS, 2022
Published: Apr 27, 2022 | Tags: Pfizer, BioNTech, US, FDA, EUA, Booster Dose, COVID-19 Vaccine, Children,
Protagonist Reports Results of PN-943 in P-II (IDEAL) Study for the Treatment of Ulcerative Colitis
Published: Apr 27, 2022 | Tags: Protagonist, PN-943, P-II, IDEAL Study, Ulcerative Colitis
Published: Apr 27, 2022 | Tags: Daiichi Sankyo, AstraZeneca, Enhertu, US, FDA, Breakthrough Therapy Designation, HER2, Breast Cancer
Published: Apr 26, 2022 | Tags: Gamida Cell, US, FDA, IND, Clinical Hold, GDA-201, Follicular, Diffuse Large B Cell Lymphoma
Published: Apr 26, 2022 | Tags: Valneva, Pfizer, VLA15, P-II, VLA15-221 Trial, Lyme Disease
Bergenbio Reports Results of Bemcentinib in P-II (ACCORD2) Study for the Treatment of COVID-19
Published: Apr 26, 2022 | Tags: Bergenbio, Bemcentinib, P-II, ACCORD2 Study, COVID-19
Abbott Launches Upgraded Version of NeuroSphere myPath Digital Health App to Boost Connected Care Technology for Chronic Pain
Published: Apr 26, 2022 | Tags: Abbott, Launches, NeuroSphere myPath Digital Health App, Connected Care Technology, Chronic Pain
Published: Apr 26, 2022 | Tags: AstraZeneca, US, FDA, BLA, Priority Review, Tremelimumab, Hepatocellular Carcinoma
Published: Apr 26, 2022 | Tags: Gilead, Veklury, remdesivir, US, FDA, sNDA, Approval, COVID-19
Mundipharma and Cidara Present Results of Rezafungin in P-III (ReSTORE) Trial for Treatment of Candidemia or Invasive Candidiasis at ECCMID 2022
Published: Apr 25, 2022 | Tags: Mundipharma, Cidara, Rezafungin, P-III, ReSTORE, Trial, Candidemia, Invasive Candidiasis, ECCMID, 2022
Shionogi Presents Results of S-217622 in P-IIb Study for the Treatment of COVID-19 at ECCMID 2022
Published: Apr 25, 2022 | Tags: Shionogi, S-217622, P-IIb Study, COVID-19, ECCMID, 2022
Amryt Receives CHMP Positive Opinion of Filsuvez for the Treatment of Dystrophic and Junctional EB
Published: Apr 25, 2022 | Tags: Amryt, CHMP, Positive Opinion, Filsuvez, Dystrophic, Junctional EB
Gilead Presents Results of Veklury (remdesivir) in Multiple Studies for COVID-19 at ECCMIC 2022
Published: Apr 25, 2022 | Tags: Gilead, Veklury, remdesivir, Multiple, Studies, COVID-19, ECCMIC, 2022
Published: Apr 25, 2022 | Tags: Incyte, CHMP, Tabrecta, capmatinib, METex14, Non-Small Cell Lung Cancer
Published: Apr 25, 2022 | Tags: Scynexis, Ibrexafungerp, P-III, FURI, CARES Studies, Fungal Infections
Related Post: PharmaShots Weekly Snapshots (April 18-22, 2022)
Tags
Dr. Anish Desai is a trained Clinical Pharmacologist and Pharmaceutical Physician with 3 decades of experience in Academia, Research, and Healthcare industry with proven leadership skills, strong business acumen, and a deep understanding of the Healthcare System, including Pharmaceutical, Nutraceutical & Medical device industry. He has been recognized for driving positive change, delivering solutions, developing talent and nurturing strong relationships with external stakeholders. Holding Senior Management Position for last 20 years and involved in strategic decision making. 'IntelliMed Healthcare Solutions' is a Healthcare startup launched by him with an intent to focus on strategic medical affairs for business growth, thereby infusing science into business. IntelliMed specializes in scientific, Clinical & medical support from conceptualization/Ideation to launch.
